ATXI — Avenue Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.27m
- -$0.67m
- $1.40m
Brief: Avenue Therapeutics Files For Mixed Shelf Of Up To $30 Mln
Brief: Avenue Therapeutics Announces FDA Advisory Committee Meeting To Review IV Tramadol NDA Tentatively Scheduled For February 15, 2022
Brief: Avenue Therapeutics Announces Closing Of Public Offering Of Common Stock
Brief: Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering Of Common Stock
Brief: Avenue Therapeutics Says Delivered To Invagen Pharmaceuticals Notice Of Termination Of Stock Purchase & Merger Agreement
Brief: Avenue Therapeutics Receives Interim Response To Its Formal Dispute Resolution Request From U.S. FDA Office Of New Drugs
Brief: Avenue Therapeutics Inc Says Co Received An Acknowledgement Letter From Office Of New Drugs Of Food And Drug Administration
Brief: Avenue Therapeutics Submitted Formal Dispute Resolution Request To FDA
Avenue falls after FDA turns down co's appeal regarding painkiller
Brief: Avenue Therapeutics Inc - On August 26, Co Received An Appeal Denied Letter From Office Of Neuroscience Of FDA
Avenue Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Avenue Therapeutics Submits FDRR To FDA With Respect To CRLs Previously Issued Related To Its IV Tramadol NDA
Brief: Fortress Biotech - Avenue Therapeutics Intends To Continue To Pursue Approval For IV Tramadol
U.S. STOCKS ON THE MOVE-Washington Prime Group, Qudian, PDS Biotech
U.S. STOCKS ON THE MOVE-Sage Therapeutics, Clearside Biomedical, Enzo Biochem
U.S. STOCKS ON THE MOVE-Lordstown Motors, RAPT Therapeutics, AMC Entertainment
U.S. FDA declines to approve Avenue's IV formulation of non-opioid painkiller (updated)
U.S. STOCKS ON THE MOVE-Washington Prime Group, RAPT Therapeutics, Enochian Biosciences
Brief: Avenue Therapeutics Receives Complete Response Letter From The FDA For IV Tramadol